Company intelligence
Qkine
High quality and novel growth factors for stem cell and organoid culture, regenerative medicine and cellular agriculture
About Qkine
Qkine manufactures high-quality and novel growth factors, supporting scientists in developing and scaling stem cell, organoid, cellular agriculture and regenerative medicine applications. We are also developing new growth factor technologies to enable emerging fields such as cultured meat and 3D cell culture. All Qkine high purity animal-free growth factor proteins are manufactured at our facility in Cambridge, UK . Extensive quality testing is conducted on every lot to guarantee reproducibility. Based on proprietary technology developed in the laboratory of Dr Marko Hyvönen, senior group leader at the University of Cambridge, Qkine manufactures highly pure bioactive recombinant proteins. Along with setting a new benchmark for protein purity, Qkine uses protein engineering techniques to tackle fundamental biological and scalability challenges that are holding back the stem cell and regenerative medicine sector; for example, recent projects have included development of optimised R-spondins to replace conditioned media for organoid culture. To give stem cell scientists peace of mind, Qkine manufactures its proteins in a dedicated animal-derived component-free (ADCF) laboratory under an ISO 9001:2015. We define rigorous quality criteria, with detailed data. Bulk orders and stock reservations are available. For more information please visit www.qkine.com, or contact the Qkine Team at info@qkine.com
Verified activity
Signals from Qkine
11 published signals
Presence & Recognition
Qkine is attending the second PluriCon meeting hosted by Pluristyx, Inc. on 17 September 2026.
Reported by Qkine
Presence & Recognition
Qkine and BioLife Solutions, Inc. are hosting a live webinar with Cell & Gene Therapy Review on Wednesday, September 23rd, 2026, featuring Dave Briner and Liz Stewart on cytokine quality control and closed system technologies for cell and gene therapy workflows.
Reported by Qkine
Presence & Recognition
Qkine hosted a webinar jointly hosted with BioLife Solutions, Inc.
Reported by Rob Nixon
Research & Knowledge
Qkine published an application note detailing the differentiation of feeder-free human induced pluripotent stem cells (iPSCs) into neuroectodermal cells using Qk053, Qk034, and Qk120 proteins.
Reported by Qkine
Capital & Finance
Qkine secured a £1.6 million funding round in which CPI Enterprises and EverQuest Capital Partners co-invested alongside Parkwalk and EMV Capital plc.
Reported by Qkine
Capital & Finance
Qkine secured a £1.5 million investment to accelerate stem cell innovation.
Reported by Qkine
Presence & Recognition
Qkine is attending the Human Development: Stem Cells, Models, Embryos meeting at the University of Warwick on 7-9 September 2026.
Reported by Qkine
Presence & Recognition
Qkine will be staying local at the Gastruloids & Embryoids Workshop 2026 at the University of Cambridge on the 21st to 22nd September.
Reported by Qkine
Presence & Recognition
Qkine will be exhibiting at the Human Development: Stem Cells, Models, Embryos meeting at the University of Warwick on the 7th to 9th September.
Reported by Qkine
Presence & Recognition
Qkine Senior Product Manager Liz Stewart will be serving as the Commercial Dragon at the first Human Specific Research Community North meeting on the 3rd September.
Reported by Qkine
Presence & Recognition
Qkine Commercial Director Rob Nixon is attending the ODC26 Seoul meeting on the 17th to 18th September to connect with organoid scientists in South Korea.
Reported by Qkine